Sphingosine pathway modulating compounds for the treatment of cancers
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
1. A method for treating hepatocellular carcinoma (HCC) in a mammalian subject, consisting of the step of:
administering to a mammalian subject in need of treatment for hepatocellular carcinoma, an effective amount of the compound
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the mammalian subject is a human subject.
3. A method for inducing apoptosis of mammalian hepatocellular carcinoma (HCC) cells, consisting of the step of:
contacting the mammalian hepatocellular carcinoma cells with an effective amount of the compound
or a pharmaceutically acceptable salt thereof,
thereby inducing apoptosis of said cells.
4. The method of claim 3 , wherein the mammalian hepatocellular carcinoma cells are human hepatocellular carcinoma cells.
5. A method for treating hepatocellular carcinoma (HCC) in a mammalian subject, consisting of the step of:
administering to a mammalian subject in need of treatment for hepatocellular carcinoma, a pharmaceutical composition consisting of:
(i) an effective amount of the compound
or a pharmaceutically acceptable salt thereof, and
(ii) at least one pharmaceutically acceptable excipient.
6. The method of claim 5 , wherein the mammalian subject is a human subject.